Does progesterone prevent recurrent spontaneous abortion (RSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Progesterone does not have sufficient evidence to prevent recurrent pregnancy loss, and its use for this purpose is not supported by the provided study. The study by da Fonseca et al 1 focused on the prevention of preterm birth in women with singleton pregnancy and prior preterm birth, rather than recurrent pregnancy loss. Although progesterone has been shown to reduce the incidence of preterm birth at <37 weeks of gestation (28.5% to 13.8%, P = .03) and <34 weeks of gestation (18.6% to 2.7%, P = .002) in this context, its effectiveness in preventing recurrent pregnancy loss is not established by this study. Some key points to consider when evaluating the use of progesterone for recurrent pregnancy loss include:

  • The lack of direct evidence from the provided study to support its use for this specific indication
  • The potential benefits of progesterone in other obstetric contexts, such as preterm birth prevention, as demonstrated by da Fonseca et al 1
  • The need for comprehensive evaluation of women with recurrent pregnancy loss to identify underlying causes that may require alternative treatments. In clinical practice, the decision to use progesterone for recurrent pregnancy loss should be made on a case-by-case basis, taking into account the individual patient's medical history, underlying causes of recurrent loss, and potential benefits and risks of progesterone therapy.

From the Research

Evidence for Progesterone in Preventing Recurrent Pregnancy Loss

  • The use of progesterone supplementation in preventing recurrent pregnancy loss is mentioned in several studies 2, 3, 4.
  • A study published in 2024 suggests that vaginal progesterone supplementation may be considered in patients experiencing vaginal bleeding during the first trimester 2.
  • Another study from 2017 mentions that progesterone supplementation is used as an empirical treatment for unexplained recurrent pregnancy loss 3.
  • A 2020 study notes that available treatments for recurrent pregnancy loss target putative risk factors, including endometrial dysfunction, which may be addressed with progesterone supplementation 5.
  • A 2018 study specifically examines the role of progestogens, including progesterone, in preventing pregnancy loss and finds a beneficial effect in luteal-phase support, threatened miscarriage, and recurrent miscarriage 4.

Effectiveness of Progesterone Supplementation

  • The 2018 study reports that progestogens are associated with a higher rate of live births or ongoing pregnancy in the progesterone group, with an odds ratio of 1.77 (95% CI 1.09-2.86) 4.
  • The same study also finds that progestogens are effective in treating threatened miscarriage, with a reduced odds ratio of 0.53 (95% CI 0.35-0.79) 4.
  • A meta-analysis cited in the 2018 study shows a 28% increase in the live birth rate with progestational agents in recurrent miscarriage (relative risk 0.72,95% CI 0.53-0.97) 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Evaluation of Recurrent Pregnancy Loss.

Obstetrics and gynecology, 2024

Research

Recurrent pregnancy loss: current perspectives.

International journal of women's health, 2017

Research

Progestogens and pregnancy loss.

Climacteric : the journal of the International Menopause Society, 2018

Research

Recurrent pregnancy loss.

Nature reviews. Disease primers, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.